Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM. Deibele AJ, et al. Among authors: jennings lk. Circulation. 2010 Feb 16;121(6):784-91. doi: 10.1161/CIRCULATIONAHA.109.882746. Epub 2010 Feb 1. Circulation. 2010. PMID: 20124127 Clinical Trial.
Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.
Tardiff BE, Jennings LK, Harrington RA, Gretler D, Potthoff RF, Vorchheimer DA, Eisenberg PR, Lincoff AM, Labinaz M, Joseph DM, McDougal MF, Kleiman NS; PERIGEE Investigators. Tardiff BE, et al. Among authors: jennings lk. Circulation. 2001 Jul 24;104(4):399-405. doi: 10.1161/hc2901.093500. Circulation. 2001. PMID: 11468200 Clinical Trial.
Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy.
Gibson CM, Jennings LK, Murphy SA, Lorenz DP, Giugliano RP, Harrington RA, Cholera S, Krishnan R, Califf RM, Braunwald E; INTEGRITI Study Group. Gibson CM, et al. Among authors: jennings lk. Circulation. 2004 Aug 10;110(6):679-84. doi: 10.1161/01.CIR.0000137912.11655.F6. Epub 2004 Jul 19. Circulation. 2004. PMID: 15262838 Clinical Trial.
No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.
Kosoglou T, Reyderman L, Kasserra C, Jennings LK, Young S, Xuan F, Pei J, Maxwell SE, Schiller J, Meehan AG, Cutler DL. Kosoglou T, et al. Among authors: jennings lk. Eur J Clin Pharmacol. 2012 Mar;68(3):291-300. doi: 10.1007/s00228-011-1127-z. Epub 2011 Oct 4. Eur J Clin Pharmacol. 2012. PMID: 21969227 Clinical Trial.
Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial.
Li JS, Yow E, Berezny KY, Bokesch PM, Takahashi M, Graham TP Jr, Sanders SP, Sidi D, Bonnet D, Ewert P, Jennings LK, Michelson AD; PICOLO Investigators. Li JS, et al. Among authors: jennings lk. Circulation. 2008 Jan 29;117(4):553-9. doi: 10.1161/CIRCULATIONAHA.107.715821. Epub 2008 Jan 14. Circulation. 2008. PMID: 18195173 Clinical Trial.
Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.
Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shattil SJ, Randolph A, Jakubowski JA, Jennings LK, Scarborough RM. Phillips DR, et al. Among authors: jennings lk. Circulation. 1997 Sep 2;96(5):1488-94. doi: 10.1161/01.cir.96.5.1488. Circulation. 1997. PMID: 9315536
181 results